| CASE REPORT |
|
| Year : 2022 | Volume
: 4
| Issue : 2 | Page : 89-91 |
|
|
Is remdesivir-induced symptomatic bradycardia persistent? A two case report of COVID-19 infection
Rime Mehannek1, Krunal Truvedi1, Kinjal Patel2, Ahsan Khan2
1 Department of Internal Medicine, St. Michael's Medical Center, Affiliated with New York Medical College, Newark, New Jersey, USA
2 Department of Cardiology, St. Michael's Medical Center, Affiliated with New York Medical College, Newark, New Jersey, USA
Correspondence Address:
Dr. Rime Mehannek
111 Central Avenue, Newark, New Jersey, 07102
USA
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ACCJ.ACCJ_12_22
|
|
|
As of May 2022, a total of over 528 million cases of coronavirus 19 disease (COVID-19) worldwide with over 6 million deaths. Remdesivir is a broad-spectrum antiviral medication approved worldwide; it acts by inhibiting the RNA-dependent RNA polymerase, used for moderate-to-severe COVID-19 which requires supplemental oxygen but not intubation. Not shown to improve mortality but shorten the recovery time, especially if given within the first 10 days of symptom initiation. Despite its worldwide use, its cardiovascular safety profile has not been determined as yet. Herein, we report two cases of COVID-19 infection who develop symptomatic bradycardia on a 5-day course of remdesivir.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
